本研究旨在评价Ki-67列线图对胶质瘤患者总生存期和无病生存期的预测价值，共纳入了滕州市中心人民医院经病理诊断为胶质瘤的76名患者。从医疗记录中回顾性收集基线数据和随访数据。使用对数秩检验、单变量和多变量 Cox 比例风险回归模型检查 Ki-67 与生存状态之间的关联。进行校准以验证所建立的列线图。通过对数秩检验，Ki-67阴性组显示出更长的OS生存时间和更长的PFS生存时间（x2 = 16.101，P < 0.001和x2 = 16.961，P < 0.001）。年龄超过 50 岁（HR = 2.074，95% CI 1.097-3.923）、治疗异常（HR = 2.932，95% CI 1.343-6.403）和 Ki-67 阳性（HR = 2.722，95% CI 1.097-6.755）死亡的独立预测因素。高级别病理（HR = 2.453，95% CI 1.010-5.956）和Ki-67阳性（HR = 2.200，95% CI 1.043-4.639）是复发的独立预测因素。 OS 和 PFS 列线图的 C 指数分别为 0.745 和 0.723。校准结果表明列线图可以预测神经胶质瘤患者的总体无病1年生存率。总之，以 Ki-67 作为 OS 和 PFS 独立危险因素的列线图可以为恶性胶质瘤的治疗和随访提供临床咨询。© 2024。作者。

This study examined to evaluate the predictive value of a nomogram with Ki-67 in overall and disease-free survival in glioma patients, a total of 76 patients diagnosed with glioma by pathology in Tengzhou Central People's Hospital were enrolled. The baseline data and follow ups were retrospectively collected from medical records. The associations between Ki-67 and survival status were examined using log-rank test, univariate and multivariate Cox proportional hazard regression models. Calibrations were performed to validate the established nomograms. Ki-67 negative group showed of a longer OS survival time and a longer PFS survival time with log-rank test (x2 = 16.101, P < 0.001 and x2 = 16.961, P < 0.001). Age older than 50 years (HR = 2.074, 95% CI 1.097-3.923), abnormal treatment (HR = 2.932, 95% CI 1.343-6.403) and Ki-67 positive (HR = 2.722, 95% CI 1.097-6.755) were the independent predictive factors of death. High grade pathology (HR = 2.453, 95% CI 1.010-5.956) and Ki-67 positive (HR = 2.200, 95% CI 1.043-4.639) were the independent predictive factors of recurrence. The C-index for the nomogram of OS and PFS were 0.745 and 0.723, respectively. The calibration results showed that the nomogram could predict the overall and disease-free 1-year survival of glioma patients. In conclusion, the nomograms with Ki-67 as independent risk factor for OS and PFS could provide clinical consultation in the treatment and follow-up of malignant glioma.© 2024. The Author(s).